March 17, 2022
Eisai CEO Haruo Naito Eisai is set to ramp up its focus on its Alzheimer’s drug candidate lecanemab following an amendment to its Aduhelm (aducanumab) collaboration pact with Biogen, CEO Haruo Naito said on a conference call on March 16...read more